<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>361</serviceExecutionTime><Drug id="2675"><DrugName>BRL-35135</DrugName><DrugSynonyms><Name><Value>BRL-35135</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BRL-35135A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>86615-96-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>86615-41-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19962">SmithKline Beecham plc</CompanyOriginator><CompaniesSecondary><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Company id="19962">SmithKline Beecham plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18278" type="Company"><TargetEntity id="4295877793" type="organizationId">Mochida Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19962" type="Company"><TargetEntity id="5000780276" type="organizationId">Smithkline Beecham Ltd</TargetEntity></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"></TargetEntity><TargetEntity id="D015212" type="MeSH"></TargetEntity><TargetEntity id="-156308446" type="omicsDisease"></TargetEntity><TargetEntity id="394" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="258" type="ciIndication"><TargetEntity id="K27" type="ICD10"></TargetEntity><TargetEntity id="10034341" type="MEDDRA"></TargetEntity><TargetEntity id="D010437" type="MeSH"></TargetEntity><TargetEntity id="-1581037299" type="omicsDisease"></TargetEntity><TargetEntity id="409" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="42" type="Action"><TargetEntity id="61" type="Mechanism">beta3-Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="72" type="Action"><TargetEntity id="1052" type="Mechanism">Lipid Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="PTGT-00074" type="ciTarget"><TargetEntity id="16144822471553" type="siTarget">Beta-3 adrenergic receptor</TargetEntity><TargetEntity id="1074885228" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="189">Inflammatory bowel disease</Indication><Indication id="238">Obesity</Indication><Indication id="258">Peptic ulcer</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="42">Beta 3 adrenoceptor agonist</Action><Action id="1919">Insulin sensitizer</Action></ActionsPrimary><ActionsSecondary><Action id="1732">Energy metabolism modulator</Action><Action id="399">Hypoglycemic agent</Action><Action id="72">Antihyperlipidemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra><Ephmra><Code>C10</Code><Name>HYPOLIPIDAEMICS/ANTI-ATHEROMA PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T10:19:36.000Z</LastModificationDate><ChangeDateLast>2009-03-19T15:13:04.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="2675" linkType="Drug"&gt;BRL-35135&lt;/ulink&gt; is a beta 3 adrenoceptor agonist that was under development by &lt;ulink linkID="19962" linkType="Company"&gt;SmithKline Beecham&lt;/ulink&gt; and licensed to Mochida. It had reached phase II clinical trials in the UK as an antidiabetic. &lt;ulink linkID="19962" linkType="Company"&gt;SmithKline Beecham&lt;/ulink&gt; suspended development of the drug in 1992 and in August 1995, Mochida confirmed that it too had discontinued development.&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="2675" linkType="Drug"&gt;BRL-35135&lt;/ulink&gt; can be given orally, improves insulin sensitivity and increases glucose tolerance [&lt;ulink linkID="15130" linkType="reference"&gt;15130&lt;/ulink&gt;]. An indication as to the mechanism of action is obtained from results in rodents: &lt;ulink linkID="5511" linkType="Drug"&gt;BRL-37344&lt;/ulink&gt;, the active metabolite of &lt;ulink linkID="2675" linkType="Drug"&gt;BRL-35135&lt;/ulink&gt;, interacts with a beta-adrenoceptor present on brown adipose tissue [&lt;ulink linkID="15131" linkType="reference"&gt;15131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="2675" linkType="Drug"&gt;BRL-35135&lt;/ulink&gt; could have therapeutic potential against inflammatory bowel disease and peptic ulceration according to Glaxo's patent application EP-00713698.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>1995-08-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="258">Peptic ulcer</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="238">Obesity</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="258">Peptic ulcer</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="238">Obesity</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="258">Peptic ulcer</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="258">Peptic ulcer</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><Source id="162519" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00074"><Name>Beta 3 adrenoceptor</Name><SwissprotNumbers><Swissprot>O02662</Swissprot><Swissprot>O70432</Swissprot><Swissprot>P13945</Swissprot><Swissprot>P25962</Swissprot><Swissprot>P26255</Swissprot><Swissprot>P46626</Swissprot><Swissprot>Q28524</Swissprot><Swissprot>Q60483</Swissprot><Swissprot>Q95252</Swissprot><Swissprot>Q9TST4</Swissprot><Swissprot>Q9XT57</Swissprot><Swissprot>Q9XT58</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01028"><Name>Insulin receptor</Name><SwissprotNumbers><Swissprot>P06213</Swissprot><Swissprot>P09208</Swissprot><Swissprot>P15127</Swissprot><Swissprot>P15208</Swissprot><Swissprot>Q28516</Swissprot><Swissprot>Q93105</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H](Cc1ccc(cc1)OCC(=O)OC)NC[C@@H](c2cccc(c2)Cl)O.Br</Smiles><Smiles>C[C@H](Cc1ccc(cc1)OCC(=O)OC)NC[C@@H](c2cccc(c2)Cl)O</Smiles></StructureSmiles><Deals><Deal id="121808" title="Mochida to develop SB's BRL-35135 "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>